Announcement • May 22
Beijing Hotgen Biotech Co., Ltd. (SHSE:688068) announces an Equity Buyback for CNY 100 million worth of its shares. Beijing Hotgen Biotech Co., Ltd. (SHSE:688068) announces a share repurchase program. Under the program, the company will repurchase up to CNY 100 million worth of its shares. The shares will be purchased at a price not exceeding CNY 166 per share. The purpose of the program is to maintain the Company’s value and shareholder rights. Shares will be sold 12 months after the completion of the repurchase. Shares not sold within 3 years after the completion of the repurchase will be cancelled. The program will be funded from company's own funds. The program will be valid for 3 months from the Company's Directorate's Approval Date. Reported Earnings • Apr 25
Full year 2025 earnings released: CN¥2.50 loss per share (vs CN¥2.07 loss in FY 2024) Full year 2025 results: CN¥2.50 loss per share (further deteriorated from CN¥2.07 loss in FY 2024). Revenue: CN¥404.9m (down 21% from FY 2024). Net loss: CN¥216.0m (loss widened 13% from FY 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 157 percentage points per year, which is a significant difference in performance. Announcement • Apr 25
Beijing Hotgen Biotech Co., Ltd., Annual General Meeting, May 18, 2026 Beijing Hotgen Biotech Co., Ltd., Annual General Meeting, May 18, 2026, at 14:30 China Standard Time. Location: The Company's Meeting Room, Beijing China Announcement • Mar 30
Beijing Hotgen Biotech Co., Ltd. to Report Q1, 2026 Results on Apr 25, 2026 Beijing Hotgen Biotech Co., Ltd. announced that they will report Q1, 2026 results on Apr 25, 2026 New Risk • Mar 27
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Chinese stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 59% per year over the past 5 years. Reported Earnings • Mar 02
Full year 2025 earnings released: CN¥2.24 loss per share (vs CN¥2.07 loss in FY 2024) Full year 2025 results: CN¥2.24 loss per share (further deteriorated from CN¥2.07 loss in FY 2024). Revenue: CN¥407.7m (down 20% from FY 2024). Net loss: CN¥210.5m (loss widened 10% from FY 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 155 percentage points per year, which is a significant difference in performance. Announcement • Dec 26
Beijing Hotgen Biotech Co., Ltd. to Report Fiscal Year 2025 Results on Apr 25, 2026 Beijing Hotgen Biotech Co., Ltd. announced that they will report fiscal year 2025 results on Apr 25, 2026 Reported Earnings • Oct 25
Third quarter 2025 earnings released: CN¥0.29 loss per share (vs CN¥0.031 profit in 3Q 2024) Third quarter 2025 results: CN¥0.29 loss per share (down from CN¥0.031 profit in 3Q 2024). Revenue: CN¥105.8m (down 23% from 3Q 2024). Net loss: CN¥25.0m (down CN¥27.8m from profit in 3Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 177 percentage points per year, which is a significant difference in performance. Announcement • Sep 30
Beijing Hotgen Biotech Co., Ltd. to Report Q3, 2025 Results on Oct 31, 2025 Beijing Hotgen Biotech Co., Ltd. announced that they will report Q3, 2025 results on Oct 31, 2025 New Risk • Jul 30
New major risk - Revenue and earnings growth Earnings have declined by 28% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 28% per year over the past 5 years. Announcement • Jun 30
Beijing Hotgen Biotech Co., Ltd. to Report First Half, 2025 Results on Aug 30, 2025 Beijing Hotgen Biotech Co., Ltd. announced that they will report first half, 2025 results on Aug 30, 2025 Reported Earnings • May 05
First quarter 2025 earnings released: CN¥0.26 loss per share (vs CN¥0.06 profit in 1Q 2024) First quarter 2025 results: CN¥0.26 loss per share (down from CN¥0.06 profit in 1Q 2024). Revenue: CN¥93.2m (down 20% from 1Q 2024). Net loss: CN¥24.0m (down CN¥29.1m from profit in 1Q 2024). Revenue is forecast to grow 26% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Life Sciences industry in China. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 138 percentage points per year, which is a significant difference in performance. Announcement • Apr 30
Beijing Hotgen Biotech Co., Ltd., Annual General Meeting, May 22, 2025 Beijing Hotgen Biotech Co., Ltd., Annual General Meeting, May 22, 2025, at 14:30 China Standard Time. Location: The Company's Meeting Room, Beijing China Announcement • Mar 28
Beijing Hotgen Biotech Co., Ltd. to Report Q1, 2025 Results on Apr 30, 2025 Beijing Hotgen Biotech Co., Ltd. announced that they will report Q1, 2025 results on Apr 30, 2025 Reported Earnings • Mar 03
Full year 2024 earnings: EPS and revenues miss analyst expectations Full year 2024 results: CN¥1.94 loss per share (down from CN¥0.31 profit in FY 2023). Revenue: CN¥510.9m (down 5.6% from FY 2023). Net loss: CN¥179.2m (down CN¥206.6m from profit in FY 2023). Revenue missed analyst estimates by 6.3%. Earnings per share (EPS) were also behind analyst expectations. Revenue is forecast to grow 21% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Life Sciences industry in China. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 101 percentage points per year, which is a significant difference in performance. Announcement • Dec 27
Beijing Hotgen Biotech Co., Ltd. to Report Fiscal Year 2024 Results on Apr 30, 2025 Beijing Hotgen Biotech Co., Ltd. announced that they will report fiscal year 2024 results on Apr 30, 2025 New Risk • Nov 19
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 5.0% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (11% average weekly change). Announcement • Nov 15
Beijing Hotgen Biotech Co., Ltd. (SHSE:688068) announces an Equity Buyback for CNY 100 million worth of its shares. Beijing Hotgen Biotech Co., Ltd. (SHSE:688068) announces a share repurchase program. Under the program, the company will repurchase up to CNY 100 million worth of its shares. The shares will be purchased at a price not exceeding CNY 45 per share. The purpose of the program is to improve the company's long-term incentive mechanism, fully mobilize the enthusiasm of the employees, and jointly promote the company's long-term development. The repurchased shares will be used to protect the company's value and shareholders' rights, otherwise will be cancelled if the company fails to transfer them within the time limit stipulated by relevant laws and regulations. The program will be funded from company's own funds or special loan funds. The program will be valid for 3 months. The company had 92,474,692 shares outstanding. New Risk • Oct 31
New major risk - Revenue and earnings growth Earnings have declined by 5.0% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 5.0% per year over the past 5 years. Minor Risk Paying a dividend despite being loss-making. Announcement • Sep 30
Beijing Hotgen Biotech Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024 Beijing Hotgen Biotech Co., Ltd. announced that they will report Q3, 2024 results on Oct 31, 2024 Announcement • Jun 29
Beijing Hotgen Biotech Co., Ltd. to Report First Half, 2024 Results on Aug 30, 2024 Beijing Hotgen Biotech Co., Ltd. announced that they will report first half, 2024 results on Aug 30, 2024 New Risk • May 18
New minor risk - Dividend sustainability The company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 0.7% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. This is currently the only risk that has been identified for the company. Announcement • May 01
Beijing Hotgen Biotech Co., Ltd., Annual General Meeting, May 21, 2024 Beijing Hotgen Biotech Co., Ltd., Annual General Meeting, May 21, 2024, at 14:30 China Standard Time. Location: The Company's Meeting Room, Beijing China Reported Earnings • Apr 30
Full year 2023 earnings released: EPS: CN¥0.31 (vs CN¥10.33 in FY 2022) Full year 2023 results: EPS: CN¥0.31 (down from CN¥10.33 in FY 2022). Revenue: CN¥541.3m (down 85% from FY 2022). Net income: CN¥27.4m (down 97% from FY 2022). Profit margin: 5.1% (down from 27% in FY 2022). Over the last 3 years on average, earnings per share has fallen by 35% per year but the company’s share price has fallen by 42% per year, which means it is performing significantly worse than earnings. Announcement • Mar 29
Beijing Hotgen Biotech Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024 Beijing Hotgen Biotech Co., Ltd. announced that they will report Q1, 2024 results on Apr 30, 2024 Reported Earnings • Feb 29
Full year 2023 earnings released: EPS: CN¥0.34 (vs CN¥10.33 in FY 2022) Full year 2023 results: EPS: CN¥0.34 (down from CN¥10.33 in FY 2022). Revenue: CN¥541.1m (down 85% from FY 2022). Net income: CN¥30.2m (down 97% from FY 2022). Profit margin: 5.6% (down from 27% in FY 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 35% per year but the company’s share price has increased by 8% per year, which means it is well ahead of earnings. Announcement • Feb 08
Beijing Hotgen Biotech Co., Ltd. (SHSE:688068) announces an Equity Buyback for CNY 150 million worth of its shares. Beijing Hotgen Biotech Co., Ltd. (SHSE:688068) announces a share repurchase program. Under the program, the company will repurchase up to CNY 150 million worth of its A shares. The shares will be repurchased at a price of not more than CNY 53 per share. The purpose of the program is to protect the company's value and shareholders' rights. The source of funds for the share repurchase is the company's own funds. The program will be valid till 3 months. Announcement • Dec 30
Beijing Hotgen Biotech Co., Ltd. to Report Fiscal Year 2023 Results on Apr 30, 2024 Beijing Hotgen Biotech Co., Ltd. announced that they will report fiscal year 2023 results on Apr 30, 2024 Reported Earnings • Nov 01
Third quarter 2023 earnings released: CN¥0.34 loss per share (vs CN¥3.12 profit in 3Q 2022) Third quarter 2023 results: CN¥0.34 loss per share (down from CN¥3.12 profit in 3Q 2022). Revenue: CN¥99.9m (down 90% from 3Q 2022). Net loss: CN¥30.4m (down 111% from profit in 3Q 2022). Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has increased by 13% per year, which means it is well ahead of earnings. Valuation Update With 7 Day Price Move • Oct 23
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to CN¥37.70, the stock trades at a trailing P/E ratio of 15.7x. Average trailing P/E is 33x in the Life Sciences industry in China. Total returns to shareholders of 31% over the past three years. New Risk • Oct 20
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 6.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (24% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (6.0% average weekly change). Profit margins are more than 30% lower than last year (12% net profit margin). Reported Earnings • Aug 31
Second quarter 2023 earnings released: EPS: CN¥0.29 (vs CN¥2.27 in 2Q 2022) Second quarter 2023 results: EPS: CN¥0.29 (down from CN¥2.27 in 2Q 2022). Revenue: CN¥104.1m (down 85% from 2Q 2022). Net income: CN¥25.9m (down 88% from 2Q 2022). Profit margin: 25% (down from 31% in 2Q 2022). Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth. Announcement • Jun 28
Beijing Hotgen Biotech Co., Ltd. to Report First Half, 2023 Results on Aug 30, 2023 Beijing Hotgen Biotech Co., Ltd. announced that they will report first half, 2023 results on Aug 30, 2023 Reported Earnings • Mar 02
Full year 2022 earnings released: EPS: CN¥12.13 (vs CN¥23.74 in FY 2021) Full year 2022 results: EPS: CN¥12.13 (down from CN¥23.74 in FY 2021). Revenue: CN¥3.57b (down 34% from FY 2021). Net income: CN¥1.12b (down 49% from FY 2021). Profit margin: 31% (down from 41% in FY 2021). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 72% per year but the company’s share price has only increased by 10% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Dec 16
Investor sentiment deteriorated over the past week After last week's 17% share price decline to CN¥78.83, the stock trades at a trailing P/E ratio of 4x. Average trailing P/E is 49x in the Life Sciences industry in China. Total returns to shareholders of 166% over the past three years. Valuation Update With 7 Day Price Move • Nov 21
Investor sentiment improved over the past week After last week's 28% share price gain to CN¥87.96, the stock trades at a trailing P/E ratio of 4.5x. Average trailing P/E is 55x in the Life Sciences industry in China. Total returns to shareholders of 223% over the past three years. Valuation Update With 7 Day Price Move • Nov 07
Investor sentiment improved over the past week After last week's 17% share price gain to CN¥69.43, the stock trades at a trailing P/E ratio of 3.5x. Average trailing P/E is 52x in the Life Sciences industry in China. Total returns to shareholders of 137% over the past three years. Reported Earnings • Oct 25
Third quarter 2022 earnings released: EPS: CN¥3.12 (vs CN¥0.26 in 3Q 2021) Third quarter 2022 results: EPS: CN¥3.12 (up from CN¥0.26 in 3Q 2021). Revenue: CN¥963.5m (up 392% from 3Q 2021). Net income: CN¥286.7m (up CN¥263.0m from 3Q 2021). Profit margin: 30% (up from 12% in 3Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 91% per year but the company’s share price has only increased by 17% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Oct 18
Investor sentiment improved over the past week After last week's 15% share price gain to CN¥60.56, the stock trades at a trailing P/E ratio of 3.6x. Average trailing P/E is 49x in the Life Sciences industry in China. Total returns to shareholders of 55% over the past three years. Announcement • Sep 07
Beijing Hotgen Biotech Co., Ltd. (SHSE:688068) announces an Equity Buyback for CNY 300 million worth of its shares. Beijing Hotgen Biotech Co., Ltd. (SHSE:688068) announces a share repurchase program. Under the program, the company will repurchase up to CNY 300 million worth of shares. The shares will be repurchased at a price of not more than CNY 98.11 per share. The shares purchased will be used for the company's equity incentive plan or ESOP. The program will be valid till 12 months. Reported Earnings • Apr 29
Full year 2021 earnings: EPS and revenues miss analyst expectations Full year 2021 results: EPS: CN¥35.14 (up from CN¥1.80 in FY 2020). Revenue: CN¥5.37b (up CN¥4.86b from FY 2020). Net income: CN¥2.19b (up CN¥2.07b from FY 2020). Profit margin: 41% (up from 22% in FY 2020). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 12%. Earnings per share (EPS) also missed analyst estimates by 42%. Valuation Update With 7 Day Price Move • Apr 14
Investor sentiment improved over the past week After last week's 19% share price gain to CN¥213, the stock trades at a trailing P/E ratio of 6x. Average trailing P/E is 59x in the Life Sciences industry in China. Total returns to shareholders of 114% over the past year. Valuation Update With 7 Day Price Move • Mar 14
Investor sentiment improved over the past week After last week's 19% share price gain to CN¥200, the stock trades at a trailing P/E ratio of 5.7x. Average trailing P/E is 63x in the Life Sciences industry in China. Total returns to shareholders of 393% over the past year. Reported Earnings • Mar 02
Full year 2021 earnings: EPS and revenues miss analyst expectations Full year 2021 results: EPS: CN¥35.26 (up from CN¥1.80 in FY 2020). Revenue: CN¥5.37b (up CN¥4.86b from FY 2020). Net income: CN¥2.19b (up CN¥2.08b from FY 2020). Profit margin: 41% (up from 22% in FY 2020). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 12%. Earnings per share (EPS) also missed analyst estimates by 42%. Valuation Update With 7 Day Price Move • Feb 17
Investor sentiment improved over the past week After last week's 16% share price gain to CN¥145, the stock trades at a trailing P/E ratio of 5.7x. Average trailing P/E is 66x in the Life Sciences industry in China. Total returns to shareholders of 284% over the past year. Valuation Update With 7 Day Price Move • Nov 24
Investor sentiment improved over the past week After last week's 15% share price gain to CN¥111, the stock trades at a trailing P/E ratio of 4.3x. Average trailing P/E is 91x in the Life Sciences industry in China. Total returns to shareholders of 186% over the past year. Valuation Update With 7 Day Price Move • Oct 21
Investor sentiment improved over the past week After last week's 15% share price gain to CN¥123, the stock trades at a trailing P/E ratio of 4.9x. Average trailing P/E is 106x in the Life Sciences industry in China. Total returns to shareholders of 177% over the past year. Reported Earnings • Aug 26
Second quarter 2021 earnings released: EPS CN¥13.69 (vs CN¥0.018 in 2Q 2020) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: CN¥2.37b (up CN¥2.32b from 2Q 2020). Net income: CN¥851.3m (up CN¥849.9m from 2Q 2020). Profit margin: 36% (up from 2.8% in 2Q 2020). The increase in margin was driven by higher revenue. Valuation Update With 7 Day Price Move • Jul 26
Investor sentiment deteriorated over the past week After last week's 16% share price decline to CN¥141, the stock trades at a trailing P/E ratio of 12.8x. Average trailing P/E is 94x in the Life Sciences industry in China. Total returns to shareholders of 114% over the past year. Valuation Update With 7 Day Price Move • Jun 22
Investor sentiment improved over the past week After last week's 18% share price gain to CN¥171, the stock trades at a trailing P/E ratio of 15.6x. Average trailing P/E is 94x in the Life Sciences industry in China. Total returns to shareholders of 157% over the past year. Valuation Update With 7 Day Price Move • May 24
Investor sentiment deteriorated over the past week After last week's 19% share price decline to CN¥151, the stock trades at a trailing P/E ratio of 13.8x. Average trailing P/E is 84x in the Life Sciences industry in China. Total returns to shareholders of 182% over the past year. Valuation Update With 7 Day Price Move • Apr 30
Investor sentiment improved over the past week After last week's 49% share price gain to CN¥216, the stock trades at a trailing P/E ratio of 19.7x. Average trailing P/E is 83x in the Life Sciences industry in China. Total returns to shareholders of 331% over the past year. Reported Earnings • Apr 24
First quarter 2021 earnings released: EPS CN¥9.67 (vs CN¥0.01 in 1Q 2020) The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: CN¥1.23b (up CN¥1.19b from 1Q 2020). Net income: CN¥601.3m (up CN¥600.8m from 1Q 2020). Profit margin: 49% (up from 1.3% in 1Q 2020). The increase in margin was driven by higher revenue. Valuation Update With 7 Day Price Move • Apr 13
Investor sentiment improved over the past week After last week's 26% share price gain to CN¥58.03, the stock trades at a trailing P/E ratio of 32.4x. Average trailing P/E is 80x in the Life Sciences industry in China. Total returns to shareholders of 26% over the past year. Reported Earnings • Mar 04
Full year 2020 earnings released: EPS CN¥1.79 (vs CN¥0.67 in FY 2019) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: CN¥508.7m (up 142% from FY 2019). Net income: CN¥111.5m (up 229% from FY 2019). Profit margin: 22% (up from 16% in FY 2019). The increase in margin was driven by higher revenue. Is New 90 Day High Low • Feb 05
New 90-day low: CN¥34.59 The company is down 17% from its price of CN¥41.73 on 06 November 2020. The Chinese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 40% over the same period. Is New 90 Day High Low • Dec 07
New 90-day low: CN¥37.10 The company is down 25% from its price of CN¥49.79 on 08 September 2020. The Chinese market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 8.0% over the same period. Is New 90 Day High Low • Nov 20
New 90-day low: CN¥41.40 The company is down 27% from its price of CN¥56.58 on 21 August 2020. The Chinese market is down 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 3.0% over the same period. Announcement • Oct 29
Beijing Hotgen Biotech Co., Ltd. to Report Q3, 2020 Results on Oct 30, 2020 Beijing Hotgen Biotech Co., Ltd. announced that they will report Q3, 2020 results on Oct 30, 2020 Is New 90 Day High Low • Oct 22
New 90-day low: CN¥46.23 The company is down 27% from its price of CN¥63.75 on 24 July 2020. The Chinese market is down 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is down 4.0% over the same period. Announcement • Jul 09
Beijing Hotgen Biotech Co., Ltd. to Report First Half, 2020 Results on Aug 26, 2020 Beijing Hotgen Biotech Co., Ltd. announced that they will report first half, 2020 results on Aug 26, 2020